Migraine: Epidemiology, Burden, and Comorbidity.
Burch RC, Buse DC, Lipton RB.
Neurol Clin. 2019 Nov;37(4):631-649. doi: 10.1016/j.ncl.2019.06.001. Epub 2019 Aug 27.
Migraine and Diet.
Gazerani P.
Nutrients. 2020 Jun 3;12(6):1658. doi: 10.3390/nu12061658.
Status migrainosus.
Kamourieh S, Rozen T, Anderson JM.
Handb Clin Neurol. 2024;199:413-439. doi: 10.1016/B978-0-12-823357-3.00017-3.
Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review.
Shaterian N, Shaterian N, Ghanaatpisheh A, Abbasi F, Daniali S, Jahromi MJ, Sanie MS, Abdoli A.
Pain Res Manag. 2022 Mar 31;2022:3284446. doi: 10.1155/2022/3284446. eCollection 2022.
Epidemiology of migraine.
Simmonds L, Mehta D, Cheema S, Matharu M.
Handb Clin Neurol. 2023;198:31-38. doi: 10.1016/B978-0-12-823356-6.00017-2.
Managing and Preventing Migraine in the Emergency Department: A Review.
Cortel-LeBlanc MA, Orr SL, Dunn M, James D, Cortel-LeBlanc A.
Ann Emerg Med. 2023 Dec;82(6):732-751. doi: 10.1016/j.annemergmed.2023.05.024. Epub 2023 Jul 11.
Chronic migraine: risk factors, mechanisms and treatment.
May A, Schulte LH.
Nat Rev Neurol. 2016 Aug;12(8):455-64. doi: 10.1038/nrneurol.2016.93. Epub 2016 Jul 8.
Treating status migrainosus in the emergency setting: what is the best strategy?
Vécsei L, Szok D, Nyári A, Tajti J.
Expert Opin Pharmacother. 2018 Oct;19(14):1523-1531. doi: 10.1080/14656566.2018.1516205. Epub 2018 Sep 10.
Current Status of Drug Delivery Approaches and Assay of Anti-Migraine Drugs.
Esim O, Savaser A, Karadurmus L, Bakirhan NK, Ozkan SA, Ozkan Y.
Curr Drug Deliv. 2021;18(2):121-146. doi: 10.2174/1567201817666200508094204.
Body composition status and the risk of migraine: A meta-analysis.
Gelaye B, Sacco S, Brown WJ, Nitchie HL, Ornello R, Peterlin BL.
Neurology. 2017 May 9;88(19):1795-1804. doi: 10.1212/WNL.0000000000003919. Epub 2017 Apr 12.
